Perigon Wealth Management LLC Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Perigon Wealth Management LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,007 shares of the medical research company’s stock after acquiring an additional 141 shares during the quarter. Perigon Wealth Management LLC’s holdings in IQVIA were worth $594,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in IQV. FMR LLC lifted its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in IQVIA during the 3rd quarter valued at $147,683,000. JPMorgan Chase & Co. increased its stake in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB lifted its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, KBC Group NV boosted its stake in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after purchasing an additional 250,458 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.2 %

Shares of NYSE:IQV opened at $201.34 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $36.54 billion, a P/E ratio of 26.42, a P/E/G ratio of 2.12 and a beta of 1.48. The business’s 50-day moving average is $200.42 and its 200 day moving average is $220.65. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IQV shares. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Truist Financial decreased their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Finally, Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.